Carcinogen found by pharmacy in popular U.S. diabetes drug

Valisure said Monday that its tests show high levels of N-nitrosodimethylamine (NDMA) in the diabetes drug metformin. According to the company, high levels of NDMA, which is considered a probable carcinogen, were found in 16 different batches of metformin made by 11 pharmaceutical companies.

Valisure said Monday that its tests show high levels of N-nitrosodimethylamine (NDMA) in the diabetes drug metformin. According to the company, high levels of NDMA, which is considered a probable carcinogen, were found in 16 different batches of metformin made by 11 pharmaceutical companies. One batch had NDMA levels that were up to 16 times as high as the acceptable daily limit, Valisure said. The company has filed a citizen's petition to FDA to request a recall and investigate the contaminated products. FDA said in December it was testing samples of metformin sold in the United States for NDMA. Earlier this year, the agency said it found low levels of NDMA in some metformin, although in none of the tests were levels found to be higher than the acceptable daily intake limit.